ReviewNature reviews. Urology2015
Gender differences in incidence and outcomes of urothelial and kidney cancer.
Review in Nature reviews. Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.World journal of urology · 2023Pooled it
- Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.World journal of urology · 2023Pooled it
- Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis.World journal of urology · 2019Pooled it
- Role of Second-Look Ureterorenoscopy After Endoscopic Treatment of Upper Tract Urothelial Carcinoma.Cancers · 2026Article
- Endothelial CPT2 loss impairs fatty acid oxidation and promotes renal fibrosis.Life metabolism · 2026Article
- A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients.Nature communications · 2026Article
- Kidney cancer burden in China from 1990 to 2023: A retrospective population-based observational study.The Journal of international medical research · 2026Observational
- Severe Metabolic Decompensation in Metastatic Sarcomatoid Renal Cell Carcinoma During Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Benchmarking Sparse Variable Selection Methods for Genomic Data Analyses.Statistics in medicine · 2026Article
- Sex differences in cancer incidence: prospective analyses in the UK Biobank.British journal of cancer · 2025Article
- Rising incidence and clinical impact of kidney cancer in China and worldwide: a call for targeted prevention, early diagnosis, and equitable treatment.Translational andrology and urology · 2025Article
- Global, regional, and national burden of 34 cancer groups across 204 countries and territories, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.Frontiers in oncology · 2025Article
- Sex-dimorphic tumor growth is regulated by tumor microenvironmental and systemic signals.Science advances · 2024Article
- SiRCle (Signature Regulatory Clustering) model integration reveals mechanisms of phenotype regulation in renal cancer.Genome medicine · 2024Article
- Review
- Epidemiology and Treatment Outcomes of Renal Cell Carcinoma in Qassim Region, Saudi Arabia: A Retrospective Study.Cureus · 2024Article
- Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021.Military Medical Research · 2024Article
- Article
- Changes in disease burden and global inequalities in bladder, kidney and prostate cancers from 1990 to 2019: a comparative analysis based on the global burden of disease study 2019.BMC public health · 2024Article
- Exploring the Impact of Gender-Specific Approaches inRetrograde Intrarenal Surgery: Effects on Operative Efficiency and Patient Recovery.Research and reports in urology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A gender discrepancy exists in the incidence of both urothelial and kidney carcinomas, with more men presenting with these cancers than women. Men have a threefold greater risk of developing bladder cancer than women, but female gender has been identified as an independent adverse prognostic factor for both recurrence and progression of this disease. In particular, women with bladder cancer are often diagnosed with a higher tumour stage than men. Conclusive data on the influence of gender on outcomes of patients with upper tract urothelial carcinoma are currently lacking, although men seem to have a higher disease incidence, whereas survival outcomes might be independent of gender. Patients with renal cell carcinoma are more often men and they typically have larger tumours and higher stage and grade disease than women with this cancer. Smoking habits, tumour biology, occupational risk factors and sex steroid hormones and their receptors could have a role in these observed gender disparities. The majority of data support the theory that gender influences incidence and prognosis of urothelial and kidney cancers; men and women are different genetically and socially, making the consideration of gender a key factor in the clinical decision-making process. Thus, the inclusion of this variable in validated prognostic tables and nomograms should be discussed as a matter of importance.
Indexed as
Identifiers
26436686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.